0 Items - $0.00
Categories
A to Z

Alternative structural projections:

Sp-8-BnT-cAMPS / "S-220"

8- Benzylthioadenosine- 3', 5'- cyclic monophosphorothioate, Sp- isomer ( Sp-8-BnT-cAMPS / "S-220" ), sodium salt
Potent and selective activator of Epac2 with reduced activatory potency towards PKA
Cat. No.: B 046
    
CAS No.: [pending]
Shipping: ambient
Product Name Price (net) Qty
Cat. No.: B 046-05
Unit: 5 µmol / ~2.4 mg
$250.00

For other salt forms please inquire.

According to Schwede et al. (2015), Sp-8-BnT-cAMPS potently and selectively activates Epac2 over Epac1 both in vitro and in vivo (in vitro AC50 Epac2 = 0.1 μM (1.8 µM for cAMP) and rel. kmax = 7.7 (1 for cAMP)). At concentrations of 25 to 100 µM, it potentiates glucose-induced insulin secretion from primary human islets. Sp-8-BnT-cAMPS has reduced potency to activate PKA. Detailed technical information available. Reference: Schwede et al., PLoS Biol., 13(1): e1002038 (2015) (Link to PLoS Biology).

Related products: Biolog also offers Sp-8-BnT-2'-O-Me-cAMPS (Cat. No. B 056 / "S-223") which has reduced potency compared to Sp-8-BnT-cAMPS, but efficiently discriminates against PKA, as well as the well-established Epac agonist 8-pCPT-2'-O-Me-cAMP (Cat. No. C 041) which selectively activates Epac1 over Epac2 (Schwede et al. 2015).

Cat. No. B 046
CAS number [pending]
Purity > 98% HPLC
Salt form Sodium
Storage temperature -20°C / -4°F
Molecular formula C₁₇H₁₇N₅O₅PS₂ · Na
Molecular weight [g/mol] 489.5
cAMP modified at the exocyclic oxygen axial (Sp-)
Modifications 8-cAMP
Target PKA (cAK) Activator
Lipophilicity 2.67
Absorption max [nm] 283
Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] 17100
  • 1. Schwede F., Bertinetti D., Langerijs C. N., Hadders M. A., Wienk H., Ellenbroek J. H., de Koning E. J. P., Bos J. L., Herberg F. W., Genieser H.-G., Janssen R. A.Rehmann H., PLoS Biol., 13, 1 - 26 (2015), "Structure-Guided Design of Selective Epac1 and Epac2 Agonists"